C
Century Therapeutics, Inc. (IPSC)
NCM – Real Time Price. Currency in USD
2.29
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
2.29
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.29
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
2.29
0.00 (0.00%)
After-hours: May 12, 2026, 4:10 PM EDT
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | President, CEO & Chairman |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer |
| Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer |
| Krista Kauppinen J.D., Ph.D. | VP, General Counsel & Head of Intellectual Property |
| Michael Naso Ph.D. | Senior VP of Cell Engineering |
| Mr. Douglas Carr CPA | Senior VP of Finance & Operations, Principal Financial Officer and Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-04-27 | DEF 14A | tm261507-6_def14a.htm |
| 2026-04-16 | PRE 14A | tm261507-4_pre14a.htm |
| 2026-03-12 | S-8 | tm268497d1_s8.htm |
| 2026-02-05 | S-3 | tm265318-1_s3.htm |
| 2026-01-23 | 8-K | tm263921d1_8k.htm |
| 2026-01-12 | 8-K | tm262422d3_8k.htm |
| 2026-01-08 | 8-K | tm262422d2_8k.htm |
| 2026-01-05 | S-3/A | tm261704-1_s3a.htm |
| 2025-12-29 | 8-K | tm2533998d1_8k.htm |
| 2025-12-12 | 8-K | tm2533376d1_8k.htm |
| Ms. Elizabeth Devlin | VP & Head of Development |
| Ms. Megan Bilson | Chief People Officer |